Skip to main content

Research News

 

Clinical courses

 

Clinical research courses

  • Pan-cancer analysis uncovers a new class of promising CAR T–cell immunotherapy targets

    While COL11A1 was one of the 156 targets identified that the researchers validated in mouse models, others showed promise in cell lines such as anti-fibronectin CAR T cells. Most targets have yet to be tested but are publicly available for other researchers to pursue.
  • Unraveling the roles of non-coding DNA explains childhood cancer’s resistance to chemotherapy
    Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Survival rates are over 94% due to modern therapy. However, those with relapsed or recurrent disease, often due to chemotherapy resistance, have a much poorer 30-40% survival rate.
  • Deeper understanding of malaria parasite sexual development unlocks opportunities to block disease spread

    For the first time, the developmental stages of the deadliest human malaria parasite have been mapped in high resolution, allowing researchers to understand this ever-adapting adversary in more detail than previously possible.

  • Scientists Track Doubling in Origin of Cancer Cells

    Working with human breast and lung cells, Johns Hopkins Medicine scientists say they have charted a molecular pathway that can lure cells down a hazardous path of duplicating their genome too many times, a hallmark of cancer cells.

    The findings, published May 3 in Science, reveal what goes wrong when a group of molecules and enzymes trigger and regulate what’s known as the “cell cycle,” the repetitive process of making new cells out of the cells’ genetic material.

  • Researchers Identify Biomarkers in Blood to Predict Liver Cancer
    Early detection has the potential to transform treatment and outcomes in cancer care, especially for cancers like liver cancer, which is typically diagnosed at a late stage with limited options for cure.
  • Tsetse fly protein provides anti-clotting agent with its own on-off switch
    Researchers at the University of Sydney and University of Geneva have developed a new anticoagulant, whose anticlotting action can be rapidly stopped ‘on demand’. The result could lead to new surgical and post-operative drugs that minimise the risk of serious bleeding.
  • Lower Dose of Mpox Vaccine Is Safe and Generates Six-Week Antibody Response Equivalent to Standard Regimen
    A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to findings presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Barcelona. The results suggest that antibody responses contributed to the effectiveness of dose-sparing mpox vaccine regimens used during the 2022 U.S. outbreak.
  • Physical activity in nature helps prevent several diseases, including depression and type 2 diabetes
    Physical activity in natural environments prevent almost 13,000 cases of non-communicable diseases a year in England and save treatment costs of more than 100m pound, new research from the University of Exeter has found.
  • Breast cancer rates rising among Canadian women in their 20s, 30s and 40s
    Researchers highlights need for immediate shift in public health policy as early detection is key to reducing breast cancer death and complications.
  • Use of Acid Reflux Drugs Linked to Higher Risk of Migraine
    People who take acid-reducing drugs may have a higher risk of migraine and other severe headache than people who do not take these medications, according to a study published in the April 24, 2024, online issue of Neurology®Clinical Practice, an official journal of the American Academy of Neurology.
Subscribe to Research News